Payment overview · 2025
General Payments
$475.33
22 reported records · 10 companies
Healthcare provider profile · identity verified
Nathan Trevor Simons, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BRENHAM, TX · NPI 1568502896
Verified facts
What the public records show
CMS Open Payments records show Nathan Trevor Simons, M.D. received $475.33 in general payments during 2025 across 22 reported records.
Novo Nordisk Inc accounted for 27.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $130.38 | 27.4% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $66.26 | 13.9% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $63.06 | 13.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.81 | 12.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $35.23 | 7.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.73 | 6.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.63 | 5.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.80 | 5.2% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $20.32 | 4.3% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $19.11 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $475.33 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $59.81 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $59.81 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $59.81 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $35.39 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $35.23 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.68 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.38 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.87 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.73 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.63 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.19 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $19.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 53 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 99 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
99 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
118 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 378 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 319 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 313 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 265 | 75 |
| Lisinopril | Lisinopril | 261 | 69 |
| Gabapentin | Gabapentin | 228 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 220 | 54 |
| Losartan Potassium | Losartan Potassium | 193 | 58 |
| Metformin Hcl | Metformin Hcl | 162 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 41 |
| Carvedilol | Carvedilol | 144 | 40 |
| Furosemide | Furosemide | 127 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 38 |
| Eliquis | Apixaban | 118 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 33 |
| Omeprazole | Omeprazole | 111 | 28 |
| Potassium Chloride | Potassium Chloride | 111 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 104 | 19 |
| Ozempic | Semaglutide | 99 | 19 |
| Simvastatin | Simvastatin | 98 | 26 |
| Sertraline Hcl | Sertraline Hcl | 95 | 23 |
| Nifedipine Er | Nifedipine | 81 | 20 |
| Meloxicam | Meloxicam | 77 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 22 |
| Trulicity | Dulaglutide | 74 | suppressed |
| Glipizide Er | Glipizide | 71 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | suppressed |
| Allopurinol | Allopurinol | 65 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 63 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 12 |
| Tramadol Hcl | Tramadol Hcl | 58 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 57 | 43 |
| Famotidine | Famotidine | 57 | 11 |
| Trazodone Hcl | Trazodone Hcl | 57 | 16 |
| Alendronate Sodium | Alendronate Sodium | 54 | 18 |
| Donepezil Hcl | Donepezil Hcl | 53 | 11 |
| Farxiga | Dapagliflozin Propanediol | 53 | 12 |
| Clonazepam | Clonazepam | 52 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | suppressed |
| Baclofen | Baclofen | 49 | 12 |
| Ezetimibe | Ezetimibe | 49 | 17 |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Atenolol | Atenolol | 46 | 14 |
| Lorazepam | Lorazepam | 46 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 11 |
| Spironolactone | Spironolactone | 42 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Lovastatin | Lovastatin | 38 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Alprazolam | Alprazolam | 37 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Nystatin | Nystatin | 32 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 15 |
| Celecoxib | Celecoxib | 22 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Glipizide | Glipizide | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Prednisone | Prednisone | 21 | 19 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 18 |
| Pregabalin | Pregabalin | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 11 |
| Jardiance | Empagliflozin | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 14 |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 14 |
| Finasteride | Finasteride | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Primidone | Primidone | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Zoloft | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $475.33 · 22 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, Doc Band, FARXIGA, GEMTESA, Ozempic, PREVNAR 20, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error